The trade group for the Russian pharmaceutical industry has argued for clarification to the procedure for issuing a compulsory license, to ensure that market participants can "clearly and unequivocally" understand the rules.
Compulsory licensing is a measure which compels patent owners to transfer a license to use their rights, in exchange for compensation.
The amount of compensation is determined by the law or by a predetermined mechanism.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze